Davis Polk advised J.P. Morgan Securities LLC and Citigroup Global Markets Inc. as joint book-running managers in connection with the initial public offering of 5,175,000 shares of common stock of ChemoCentryx, Inc. The gross proceeds from the offering were approximately $51.8 million. ChemoCentryx’s common stock is traded on the Nasdaq Global Select Market under the symbol “CCXI.”
Based in Mountain View, California, ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Meng Lai and Jacqueline M. Pace. Partner Rachel D. Kleinberg and associate Una Au provided tax advice. Counsel Cynthia Akard provided employment advice. Counsel Marcie A. Goldstein provided FINRA advice. The intellectual property team included associate Emma Maconick. Elizabeth J. Gordon and Nam Kim were the legal assistants for the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.
Related Posts:
- Davis Polk – ChemoCentryx, Inc. Common Stock Offering
- Davis Polk – UCP, Inc. Initial Public Offering
- Davis Polk – NanoString Technologies, Inc. Initial Public Offering
- Davis Polk – Cardiovascular Systems, Inc. Common Stock Offering
- Davis Polk – Isis Pharmaceuticals, Inc. Common Stock Offering
